Molecular Partners AG ADR

Yahoo Finance • 25 days ago

Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin th... Full story

Yahoo Finance • last month

Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting

Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimens Accelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure Six of eight responders presented with low... Full story

Yahoo Finance • 2 months ago

Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025

Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells co-expressing tumor-associated antigens MSLN... Full story

Yahoo Finance • 2 months ago

Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of cu... Full story

Yahoo Finance • 2 months ago

Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

IND application filed for MP0712, the Company’s lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images from MP0712 compassionate care program t... Full story

Yahoo Finance • 5 months ago

Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme expected in Q4 2025IND filing on first rad... Full story

Mentioned:

Yahoo Finance • 5 months ago

Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics

Molecular Partners Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE)... Full story

Mentioned:

Yahoo Finance • 7 months ago

Molecular Partners to cut jobs, cash reach now anticipated to extend into 2028

Molecular Partners (NASDAQ:MOLN [https://seekingalpha.com/symbol/MOLN]) said that it has performed a strategic review of its current operations and headcount, with the objectives of increased efficiency in the organization and to sharpen t... Full story

Yahoo Finance • 2 years ago

Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment MP0317 monotherapy shows a favorable safety profile up to the highest planned doses Patient recruitment of... Full story

Yahoo Finance • 2 years ago

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

MP0533 shows acceptable safety profile in first three dose cohorts (5 patients total, data cut-off July 20); reported adverse reactions are of Grade 1/2 and no dose-limiting toxicity observed to dateEmerging evidence of antitumor activity... Full story

Yahoo Finance • 2 years ago

Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio

MP0317 Phase 1 dose escalation recruitment completed in patients with advanced solid tumors; updated clinical results to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2023 MP0533 Phase 1/2a recru... Full story

Yahoo Finance • 2 years ago

Molecular Partners Reports H1 2023 Corporate Highlights and Financials

Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected in Q4 2023 Positive MP0317 data of ong... Full story

Yahoo Finance • 3 years ago

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 19, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin th... Full story

Yahoo Finance • 3 years ago

Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin the... Full story

Yahoo Finance • 3 years ago

Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin t... Full story

Yahoo Finance • 3 years ago

Molecular Partners Full Year 2022 Earnings: Beats Expectations

Molecular Partners (VTX:MOLN) Full Year 2022 Results Key Financial Results Revenue: CHF189.6m (up by CHF179.8m from FY 2021). Net income: CHF117.9m (up from CHF63.8m loss in FY 2021). Profit margin: 62% (up from net loss in FY 2021). The... Full story

Yahoo Finance • 3 years ago

Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of... Full story

Yahoo Finance • 3 years ago

Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML

New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagers Tri-specific T-cell engager resulted in AML cell-specific cytotoxicity with minimal off-tumor toxicityPhase I clinical tr... Full story

Yahoo Finance • 3 years ago

Molecular Partners Announces Planned Departure of Chief Financial Officer

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of c... Full story

Yahoo Finance • 3 years ago

Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End